Valneva

Valneva touts six-month chikungunya shot data

Neutralizing antibody titers produced by Valneva’s live attenuated, single-dose chikungunya vaccine candidate (VLA1553) held up in over 96% of trial participants after six months, the company announced Tuesday, citing a final analysis of Phase 3 data.

Seroprotection levels at the one-month mark confirmed topline data the French biotech shared in 2021: the Coalition for Epidemic Preparedness Innovations-backed shot generated neutralizing antibodies in nearly 99% of participants, the…

Mentions:
Valneva, chikungunya, vaccines, clinical trials, CEPI
Read more
Covid-19 development round-up: March 4, 2022

The state of the fight: 

Pfizer/BioNTech’s Comirnaty appeared to offer only 12% effectiveness against Omicron in children ages 5-11.
  South Africa’s Biovac partnered with nine development institutions to boost local vaccine manufacturing capacity.
  Eli Lilly’s arthritis drug Olumiant reduced the risk of death by 13% in hospitalized Covid-19 patients.   AUTHORIZED VACCINES

 
Pfizer/BioNTech’s Comirnaty is far less protective against infection in children ages…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, Novavax, Sinovac, Valneva, FDA, Bharat Biotech, Inovio, Shionogi, CureVac, GSK, Biovac, Gamaleya Institute, WHO, MPP, Moderna, Bio Farma, ACT-A, EMA, J&J, AstraZeneca, Merck, Regeneron, Roche, Lilly, Gilead, DNDi
Read more
Covid-19 development round-up: February 25, 2022

The state of the fight: 

Sanofi and GSK’s vaccine candidate demonstrated 58% efficacy against symptomatic Covid-19 in Phase 3.
  Hetero Pharma’s generic version of Merck’s molnupiravir reduced the risk of hospitalization by over 65%.
  Britain and Japan pledged a combined $514 million to CEPI’s pandemic preparedness plan.   AUTHORIZED VACCINES

 
The U.S. FDA lifted its clinical hold on Bharat Biotech’s Covaxin, clearing the way for the inactivated vaccine to…

Mentions:
Covid-19, vaccines, drugs, Bharat Biotech, FDA, Ocugen, Pfizer, BioNTech, CDC, Medicago, GSK, Moderna, Gamaleya Institute, CNBG, Sinopharm, EMA, CanSino, Anhui Zhifei Longcom, Sanofi, Thermo Fisher, Valneva, CEPI, AstraZeneca, Sinovac, Africa CDC, COVAX, WHO, J&J, Vir, Merck, Gilead, Shionogi, Suzhou Abogen, Walvax
Read more
Valneva tests chikungunya shot in teens

Valneva has launched an additional Phase 3 trial in Brazil of its VLA1553 live attenuated, single-dose chikungunya vaccine, the French company announced Monday.

The announcement follows previous Phase 3 data showing the Coalition for Epidemic Preparedness Innovations (CEPI)-backed shot produced neutralizing antibodies in 98.5% of participants and was well-tolerated in adults.

The new study tests the jab in adolescents ages 12 to 17 and, if successful, will support licensure in…

Mentions:
Valneva, CEPI, chikungunya, vaccines
Read more
Covid-19 development round-up: January 21, 2022

The state of the fight: 

African vaccine production advanced on multiple fronts, including the opening of a new manufacturing plant in South Africa.
  The COVAX AMC seeks an additional $5.2 billion this year.
  Merck will supply UNICEF with up to 3 million courses of molnupiravir in the first half of 2022.

AUTHORIZED VACCINES  

The Chilean health ministry released data on the Sinovac jab’s effectiveness in children. In kids ages 6-11, the topline numbers…

Mentions:
Covid-19, vaccines, drugs, WHO, Pfizer, BioNTech, Sinovac, EMA, Moderna, J&J, SII, BBIL, Novavax, Gamaleya Institute, Valneva, Clover, CEPI, IPD, COVAX, Gavi, Merck, UNICEF, MPP, GSK, Vir, Gilead, Regeneron, Roche
Read more
Covid-19 development round-up: December 23, 2021

The state of the fight: 

Oral antivirals from Pfizer and Merck notched U.S. FDA authorizations.
  Earlier use of remdesivir cut the risk of death or hospitalization by 87% in a new study.
  The Novavax vaccine secured a second WHO Emergency Use Listing.

AUTHORIZED VACCINES  

The AstraZeneca/Oxford vaccine starts waning in protection against serious illness within three months of the second dose, according to cohort studies in Brazil and Scotland published…

Mentions:
Covid-19, vaccines, drugs, AstraZeneca, IVI, CEPI, CNBG, Sinopharm, J&J, Janssen, Sinovac, Pfizer, BioNTech, Novavax, WHO, Moderna, SK Bio, EuBiologics, Gamaleya Institute, Valneva, SII, COVAX, BBIL, MPP, Merck, FDA, Gilead, GSK, Vir
Read more
Covid-19 development round-up: December 17, 2021

The state of the fight: 

WHO issued an Emergency Use Listing for Serum Institute of India’s version of Novavax’s vaccine.
  The U.S. CDC recommended mRNA-based vaccines over J&J’s.
  Data on the effectiveness of monoclonal antibody therapies against the Omicron variant began pouring in.

AUTHORIZED VACCINES  

A U.S. CDC advisory panel recommended mRNA-based vaccines over the J&J jab, citing blood clot side effects stemming from the single-dose…

Mentions:
Covid-19, vaccines, drugs, Moderna, NIH, J&J, Janssen, Pfizer, BioNTech, CanSino, SII, Novavax, WHO, EMA, COVAX, FDA, Takeda, Butantan Institute, Sinovac, BBIL, Sanofi, GSK, AstraZeneca, Valneva, CNBG, Sinopharm, Gamaleya Institute, Gavi, CEPI, Merck, Regeneron, Roche, Lilly, Vir, Novartis
Read more
Covid-19 development round-up: December 9, 2021

The state of the fight: 

New studies supported heterologous primary regimens and heterologous boosters.
  Serum Institute of India is weighing slashing Covishield production by 50%.
  The U.S. FDA OK’d AstraZeneca’s Evusheld long-acting monoclonal antibody therapy as PrEP for certain groups.

 

AUTHORIZED VACCINES  

Mixing the AstraZeneca/Oxford or Pfizer/BioNTech vaccines with a second dose of Moderna’s shot generated non-inferior immune responses …

Mentions:
Covid-19, vaccines, drugs, AstraZeneca, Pfizer, BioNTech, Moderna, Novavax, Finlay Institute, Gamaleya Institute, CureVac, J&J, Janssen, Valneva, EMA, Bavarian Nordic, Sinovac, CEPI, SII, Gavi, COVAX, Africa CDC, WHO, World Bank, UNICEF, Zydus Cadila, Thermo Fisher, Merck, FDA, GSK
Read more
Covid-19 development round-up: December 3, 2021

The state of the fight: 

A slew of vaccine manufacturers announced plans to tackle the Omicron variant.
  Aspen Pharmacare and J&J neared a deal that would let the South African manufacturer market its own version of the Janssen shot.
  Gavi’s board approved the alliance’s COVAX strategy for 2022.

AUTHORIZED VACCINES  


New research on the Pfizer/BioNTech shot affirmed its efficacy in younger people and its safety in older people.
 
…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, BBIL, FDA, Moderna, Gamaleya Institute, AstraZeneca, CNBG, Sinopharm, J&J, Janssen, Sinovac, Valneva, CEPI, Finlay Institute, Inovio, Novavax, WHO, EMA, Walvax, CureVac, Gavi, COVAX, MPP, Africa CDC, Merck, Lilly, Regeneron, Roche, GSK, Vir, Pfizer
Read more
Covid-19 development round-up: November 12, 2021

The state of the fight: 

More European countries cautioned against Moderna’s vaccine for younger people over concerns about side effects.
  Generics companies are preparing to roll out their versions of Merck’s molnupiravir oral antiviral.
  Pfizer is in talks with 90 countries over supply deals for its antiviral candidate.

 

AUTHORIZED VACCINES  


France and Germany recommended against the Moderna vaccine for people under 30 over concerns about…

Mentions:
Covid-19, vaccines, drugs, Moderna, Pfizer, BioNTech, BBIL, WHO, AstraZeneca, CanSino, Finlay Institute, CNBG, Sinopharm, Sinovac, Walvax, Inovio, Valneva, Zydus Cadila, ACT-A, BMGF, COVAX, J&J, Janssen, EuBiologics, Merck, MPP, EMA, Regeneron, Roche
Read more
Subscribe to Valneva